Viral CDMO
Choosing a CDMO That Can Grow with a Viral Program
Kai Lipinski, Ph.D.
Recipharm Advanced Bio
PAO-09-26-CL-08Oct 1, 2026
Viral Vectors
Gene Therapy Manufacturing After the Capacity Boom
David Alvaro, Ph.D.
Pharma's Almanac
PAO-10-26-PA-01Oct 1, 2026
DS + DP Integration
Integrating Drug Substance and Drug Product to Reduce Risk Across Development
Dörthe Ackenhausen
IDT Biologika
PAO-09-26-CL-02Sep 24, 2026
Vaccines
The Next Generation of Vaccine Platforms
David Alvaro, Ph.D.
Pharma's Almanac
PAO-08-26-PA-01Aug 3, 2026
Pathfinder
Lipid Nanoparticles vs. Viral Vectors for Gene Delivery: Which Platform Is Better?
Nice Insight
PAO-26-PF-11Jun 12, 2026
Continuous VV
The Stepwise Future of Continuous Viral Vector Manufacturing
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-26-PA-12Jun 1, 2026
Pathfinder
AAV vs. Lentiviral Vectors: Which Viral Vector Is Better for Gene Therapy?
Nice Insight
PAO-26-PF-09May 29, 2026
Pathfinder
CHO vs. HEK293: Which Expression System Is Better for Biopharmaceutical Production?
Nice Insight
PAO-26-PF-02Apr 10, 2026
AAV Rare Disease
Scarcity by Design: The Manufacturing Reality of AAV Gene Therapies for Rare Indications
David Alvaro, Ph.D.
Pharma's Almanac
PAO-02-26-NI-12Feb 10, 2026
Lentivirus
Vector BioMed Expands LENTIVERSE™ Platform and Unveils New Brand Identity
Vector BioMed
PR-12-25-NI-02Dec 1, 2025
Viral Vectors
Transformative Advances in Viral Vector Manufacturing: Unlocking Commercial Scalability, Consistency, and Cost-Effectiveness
Susan D'Costa, Ph.D.
Genezen
PAO-08-25-CL-08Sep 2, 2025
Gene Therapy
Build Backwards: A Framework for Rare Disease Gene Therapy Development
Farzin Farzaneh, Ph.D.; Nicholas Ostrout, Ph.D.
ViroCell Biologics
PAO-06-25-CL-09Aug 14, 2025
AAV Manufacturing
ProBio Launches GMP AAV Manufacturing Services at Hopewell Facility to Advance Gene Therapy Development and Manufacturing
ProBio Inc
PR-08-25-NI-01Aug 11, 2025
Viral Vectors
De-Risking Cell and Gene Therapies with Innovative Solutions: A Review for Leveraging a Proven Workhorse Technology in New Ways
Farzin Farzaneh, Ph.D.; Nicholas Ostrout, Ph.D.; Glenda Dickson, Ph.D.; David Darling, Ph.D.
ViroCell Biologics
PAO-06-25-CL-12Jul 31, 2025
Viral Vectors
Backbone of Innovation: How CDMO Vector Platforms Are Accelerating Gene Therapy Development
David Alvaro, Ph.D.
Pharma's Almanac
PAO-07-25-NI-09Jul 21, 2025
CGT
ProBio Opens Flagship U.S. Plasmid & Viral Vector Manufacturing Facility to Advance Cell and Gene Therapy
ProBio Inc
PR-06-25-NI-11Jun 30, 2025
Viral Vector CDMOs
Breaking Through the Noise in Viral Vector CDMO Marketing
Emilee Kudla
Pharma's Almanac
PAO-06-25-NI-10Jun 25, 2025
Neuroscience
Designer Control: DREADDs and the Next Generation of Targeted Neuromodulation
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-25-NI-11May 29, 2025
AAV
Gene Therapy at a Crossroads: Rethinking AAV Amid Industry Resets
Daniel Smith, Ph.D.
Nice Consulting
PAO-05-25-NI-02May 6, 2025
Nonviral Delivery
Rewriting the Rules of Gene Therapy with Nonviral DNA Delivery using dbDNA
Lisa Caproni
Touchlight
PAO-12-24-CL-4Dec 16, 2024